Sanofi Launches Phase III Flu-COVID Vaccine Trial in Europe, Earning Novavax $125M
Sanofi initiated a Phase III trial in Europe for a combination flu-COVID vaccine using Novavax's Nuvaxovid. Novavax received a $125 million milestone payment. The trial assesses safety and immunogenicity in adults 60+. Sanofi aims to be a leader in combination vaccines, with potential royalties and additional payments for Novavax.
How this was made

The 30-second read
Why it matters
The milestone validates the partnership and adds cash to Novavax, while the trial start provides Sanofi a potential new product line.
Market read
Both companies receive material news that could affect their stock prices; Novavax gets immediate cash, Sanofi gains a pipeline catalyst.
What to watch
Regulatory timelines and manufacturing scale‑up costs could dampen long‑term upside.
Background
The article announces the first patient dosed in a Sanofi‑Novavax Phase III flu‑COVID trial and a $125 M milestone payment to Novavax.
Ticker impact
Novavax received a $125 million milestone payment from Sanofi for the Phase III flu‑COVID vaccine trial and stands to earn further royalties and up‑to $300 million from future milestones.
upward pressure as investors price in the milestone payment and potential future royalties.
The cash milestone is material and confirms progress on a high‑profile combination vaccine, likely boosting NVAX valuation.
Sanofi launched a Phase III trial in Europe for a flu‑COVID‑19 combination vaccine using Novavax’s Nuvaxovid, marking the first patient dosed.
moderate upside as the market views the trial start as a step toward a new product line.
Phase III start is a forward‑looking catalyst; without data, price reaction is limited.
Market effects
Strengthens the vaccine/biotech sector by showing progress on combination products.
European markets may see modest uplift for vaccine manufacturers.
Highlights growing interest in multi‑pathogen vaccines worldwide.
Counterpoint
If the trial faces delays or safety issues, the initial milestone could be outweighed by future setbacks.
Key entities
- CompanyNovavax
Biotech firm receiving milestone payment and future royalties.
- CompanySanofi
Pharma company launching the Phase III combination vaccine trial.


